While patients with FXS may benefit from mGluR5 inhibitors without overt negative side effects (Berry-Kravis et al. 2009), other patients with different forms of intellectual disability may suffer profoundly from inadequate treatment with drugs like Fenobam. This evidence concerns the gene GRM5 and fragile X syndrome.